Polivy Triple Combo Approved in Europe for Select Patients with Advanced DLBCL
News
The European Commission has conditionally approved Roche’s Polivy (polatuzumab vedotin), in combination with rituximab and bendamustine, to treat people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for a hematopoietic (blood) stem cell transplant (HSCT). ... Read more